Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeannie T. Lee
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
RaNA Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
RaNA Therapeutics is a private biotechnology company focused on discovering and developing a new class of oligonucleotide medicines. RaNA’s technology platform is built upon a proprietary database of tens of thousands of gene-associated long non-coding RNAs (IncRNA) and other ncRNAs and the sequences through which they interact with the Polycomb Recessive Complex 2 (PRC2). Dr. Lee received income for Scientific Advisory Board participation and owns equity in the private company as payment for IP related to drugging IncRNA that bind Polycomb proteins. The proposed research will further develop the RNA-activation platform that is licensed to RaNA and RaNA has a significant interest in the therapeutic models and compositions arising from the research. The Co-Chairs of Partners HealthCare Conflicts of Interest Committee evaluated the financial interest in connection with this research and determined that, based on the financial interest and the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
The RNA-activation platform to treat X-linked disease in a locus-specific manner.
The proposed research will develop methods of upregulating X-linked genes through technical innovations applied to the original 'RNA-activation' technology (RNA-a; patent pending, PCT-US2011- 065939). If successful, this next-generation RNA-a methodology will have the potential to cure the dozens of intractable X-linked diseases such as Rett syndrome, Fragile X syndrome, and Duchenne muscular dystrophy. Therapeutic methods and compositions arising from this research will be of significant interest to various biotech and pharmaceutical companies, including RaNA Therapeutics, Inc.; a company that leverages lncRNAs to treat human disease and that has already licensed the original RNA-a technology.
Filed on October 29, 2013.
Tell us what you know about Jeannie T. Lee's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jeannie T. Lee filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jeannie Lee | Massachusetts General Hospital | Conflict of Interest | RaNa Therapeutics | $60,000 - $79,999 |
| Jeannie T. Lee | Massachusetts General Hospital | Conflict of Interest | RaNA Therapeutics | $40,000 - $59,999 |
| Jeannie Lee | Massachusetts General Hospital | Conflict of Interest | RaNa Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.